Breaks Categories: Stock Spotlights

ThursdaySep 15, 2022 1:38 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and,…

Continue Reading

MondayAug 22, 2022 1:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article…

Continue Reading

WednesdayAug 17, 2022 2:41 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing…

Continue Reading

TuesdayAug 02, 2022 1:53 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) patented DehydraTECH(TM) has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. Studies have also demonstrated DehydraTECH’s ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances, with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery. “DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a…

Continue Reading

WednesdayJul 27, 2022 1:32 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised with Strong In-Market Brand Portfolio, Cultivation and Export Capabilities

Flora Growth Corp. (NASDAQ: FLGC) recently reported that its board of directors had authorized the repurchase of up to $5 million of its outstanding common shares. “These recent developments highlight Flora management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment,” a recent article reads. “While making the announcement, Luis Merchan, Flora’s chairman and CEO, noted: ‘Flora continues to move assertively to execute…

Continue Reading

MondayJul 18, 2022 1:31 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised for First-Mover Advantage

Flora Growth Corp. (NASDAQ: FLGC) is aggressively pushing its brand and advancing the conversation around cannabis. “In addition, with its able management, Flora is recognizing and capitalizing on opportunities that others are yet to identify, placing it in a unique position that not only gives it a first-mover advantage but also presents a unique opportunity for growth,” a recent article that discusses a research report from Zacks reads. According to the report, 2021 saw Flora’s acquisition of Vessel Brand Inc., a move that allowed the company to establish a foothold in the United States cannabis accessories business while also improving…

Continue Reading

MondayJul 18, 2022 12:54 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently entered into agreements with beverage developer BevNology. “The BevNology collaboration not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta…. The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer-packaged-goods brands. Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility,” a recent article reads.…

Continue Reading

WednesdayJun 29, 2022 2:48 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Focused on International Strategy to Reach ‘Larger Consumer Base’

Flora Growth Corp. (NASDAQ: FLGC) CEO Luis Merchan is quoted in a recent article saying, “International growth is a key objective of our company’s strategy.” Earlier this year, the company completed the acquisition of 100% equity interests of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, in a move by Flora Growth to explore global expansion opportunities and increase its customer database. The article reads: “By mid-May 2022, Flora Growth had already announced the expansion of its operational footprint in Europe and the United Kingdom to further its international growth strategy… In what marks…

Continue Reading

WednesdayJun 29, 2022 2:28 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Stand Distinct, Push Brand

Lexaria Bioscience Corp. (NASDAQ: LEXX) acknowledges consumers’ shift away from smoking cigarettes to nicotine alternatives, which has resulted in the growth of the nicotine pouch and nicotine replacement therapy (“NRT”) markets. Through its patented DehydraTECH technology, Lexaria looks to tap into the multibillion-dollar nicotine alternatives industry and stamp its position. “In a move that sought to prove DehydraTECH’s superiority, Lexaria conducted an oral nicotine absorption study in 2021. The research showed that Lexaria’s DehydraTECH-nicotine delivered via an oral pouch product dispensed enough nicotine levels in blood plasma in four minutes, as concentration-matched controls did in 45 minutes. In addition, peak…

Continue Reading

FridayJun 17, 2022 3:23 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’

Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted tastes. “The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications… Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of…

Continue Reading